Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics?

Toh S, Li L, Harrold LR, Bayliss EA, Curtis JR, Liu L, Chen L, Grijalva CG, Herrinton LJ
Pharmacoepidemiol Drug Saf. 2012 21 (5): 524-34

PMID: 22411435 · PMCID: PMC3330193 · DOI:10.1002/pds.3238

MeSH Terms (27)

Adolescent Adult Aged Age Factors Antibodies, Monoclonal Antirheumatic Agents Autoimmune Diseases California Cohort Studies Databases, Factual Etanercept Female Follow-Up Studies Hospitalization Humans Immunoglobulin G Immunologic Factors Infections Infliximab Male Middle Aged Proportional Hazards Models Receptors, Tumor Necrosis Factor Risk Time Factors Tumor Necrosis Factor-alpha Young Adult

Connections (1)

This publication is referenced by other Labnodes entities: